Clinical Trial Update: Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical Trial Update reports the completion of a Phase 1b/2 study evaluating AMG 655 in combination with doxorubicin as first-line therapy for unresectable sof…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Soft Tissue Sarcoma

Drugs mentioned

• AMG 655 (AMG-655)
• Doxorubicin (doxorubicin)

Snippet

Sponsor: Amgen | Conditions: Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma, Sarcoma | Phase 1, Phase 2 | Status: COMPLETED